Navigation Links
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
Date:5/31/2008

xin at 60 mg/m(2). We are optimistic that the 75 mg/m(2) cohort of this Phase 2 trial will be fully enrolled by year-end, and we look forward to reporting additional efficacy and safety data later this year."

Data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in ovarian cancer were presented today during the Gynecologic Cancer: Ovarian Cancer session in a poster titled "A Phase 2 Trial of Voreloxin (formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian Cancer" (Abstract #5582). A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. In addition to the ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer, voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeloid leukemia (AML) patients, and in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therape
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
3. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
4. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015  The recent flurry of ... and employer groups scrambling to identify a pharmacy ... managed care plan, retail pharmacy chain, or other ... billion purchase of Catamaran, Rite Aid,s $2 billion ... purchase Omni-Care for $10 billion are just the ...
(Date:5/28/2015)... May 28, 2015   Sanovas, Inc., a rapidly ... the Top 50 Start-Up Companies in the World at the Silicon ... Logo - http://photos.prnewswire.com/prnh/20150528/219097LOGO ... segment experts with direct domain experience screened 2,716 companies from ... Property, Business Model, and Team. This select list was further ...
(Date:5/28/2015)... 28, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... (licensed to AstraZeneca) at the 2015 American Society of ... May 29 – June 2, 2015 in ... advancing in a total of 6 pivotal trials, with ... (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3Sanovas Awarded Global "Top-50" Start-Up Company 2Sanovas Awarded Global "Top-50" Start-Up Company 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... Risk Based on Clinical Data, ... WALTHAM, Mass., July 22 Interleukin Genetics,Inc. (Amex: ... an enhanced test report,format and information package for ... currently marketed under the brand name Gensona(R) Heart ...
... The SEAS (Simvastatin and Ezetimibe in,Aortic Stenosis) ... with the combination of simvastatin (40 mg daily) ... stenosis., Aortic stenosis (which involves partial blockage ... relatively common disease among older people in Western,populations. ...
Cached Medicine Technology:Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4
(Date:5/28/2015)... Ask not what your racquet can do for you but ... racquet. With the launch of their new digital campaign, HEAD ... tricks and unique skill to HEAD Pro Players and consumers ... artist playfully demonstrates how to gain more control over the ... also challenges tennis enthusiasts everywhere to join the show. , ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The MIT ... case study featuring Healthcare IQ. Members of the MIT ... senior management team to develop the case study about ... healthcare analytics. , The case study, ‘Healthcare IQ: Competing ... IQ from its beginning as a hospital financial software ...
(Date:5/28/2015)... First Choice Emergency Room , the ... United States, announced that it is expanding in the ... Ranch facility. , “I am pleased to announce ... quality emergency medical care to Denver residents with our ... James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:5/28/2015)... Orem, UT—Dymicron, Inc., (dymicron.com) confirmed the successful ... Triadyme-C cervical total disc replacement device. The two surgeries ... at the American Institute of Minimally Invasive Surgery (AIMIS) ... to the implantation of the Dymicron devices,” said Dr. ... Chief of Neurosurgery for the University Medical Center, Las ...
(Date:5/28/2015)... 2015 Career Step, an online provider ... announce that Career Step Executive Vice President Mike Hodgson ... webinar presented by ICD10monitor in conjunction with Kimberly J. ... Hodgson and Ms. Carr will be discussing the importance ... transition. , “We have worked closely with HRS on ...
Breaking Medicine News(10 mins):Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 2Health News:Healthcare IQ, the “Switzerland” of Healthcare Spend Analytics, Featured in MIT Case Study 3Health News:First Choice Emergency Room to Open New Facility in Denver, Colorado 2Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 3
... in fighting tooth decay has been developed by BASF, a German ... year. The company claims its// product can reduce the amount ... product was developed in collaboration with another German company OrganoBalance. ... the Streptococcus mutans (bacteria involved in tooth decay) from adhering to ...
... on junk foods and soft drinks in hospitals, schools ... of diabetes and obesity. Australia// has the world's ... with type-2 diabetes. ,In an article published ... Director of the International Diabetes Institute in Melbourne, and ...
... annual back-to-school survey on teens' attitudes that covers an overall ... practices, one// third of the American teenagers have attended parties ... were at home. ,It doesn’t imply that parents ... their homes. In fact, only 12 % of parents look ...
... According to some Swiss scientists, a new kind of breast ... is reliable.// ,Already, doctors have been using core ... ,This new test involves the study of ... more aggressive cancers that need intensive treatment. But the test ...
... fields, including math and science fields, due to their ... study. ,Researchers at RTI International, University of ... 1990 study looked at 137 female high school seniors ... later, the study found that 83 percent of those ...
... Family Health Survey for Punjab is bittersweet. While Punjab ... to retain the fertility// level at two children per woman, ... rates. Nearly 38% women and 30% men are obese, ... by CRRID in Punjab, studied nearly 3000 households. Gopal Krishan, ...
Cached Medicine News:Health News:Parents ignorant about kids' immoral practices 2Health News:Novel test for diagnosis of breast cancer 2
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Corneal Marker - 8 blades, 2 sizes available: 7.0mm, 8.0mm. 1 piece per box...
... maintains almost all its mechanical strength throughout ... in 915 months. Blunt thread design assists ... to maximize surgeons options. Driver design ... to help prevent the screw from breaking ...
... a robotic sample feeder that interfaces with the ... robotic arm and the SMS software. Continuous sample ... compatibility with clinical chemistry system racks are just ... a practical and affordable solution for improving productivity. ...
Medicine Products: